Equities analysts expect that Corium International Inc (NASDAQ:CORI) will announce earnings per share of ($0.39) for the current quarter, Zacks reports. Two analysts have issued estimates for Corium International’s earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.44). Corium International reported earnings of ($0.43) per share in the same quarter last year, which would indicate a positive year over year growth rate of 9.3%. The firm is expected to announce its next earnings report on Thursday, August 2nd.
On average, analysts expect that Corium International will report full year earnings of ($1.59) per share for the current year, with EPS estimates ranging from ($1.73) to ($1.50). For the next year, analysts forecast that the business will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.74) to ($1.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Corium International.
Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.04). Corium International had a negative return on equity of 273.01% and a negative net margin of 156.05%. The firm had revenue of $10.06 million for the quarter, compared to the consensus estimate of $7.07 million.
CORI has been the topic of several analyst reports. Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Thursday, April 5th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 price target on shares of Corium International in a research report on Tuesday, March 27th. ValuEngine raised shares of Corium International from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, BidaskClub lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $13.00.
Corium International traded down $0.20, hitting $8.01, on Friday, according to MarketBeat Ratings. 560,725 shares of the stock were exchanged, compared to its average volume of 253,928. The company has a current ratio of 8.11, a quick ratio of 7.95 and a debt-to-equity ratio of 1.89. Corium International has a 52 week low of $7.24 and a 52 week high of $13.93. The firm has a market capitalization of $290.30 million, a P/E ratio of -4.88 and a beta of 1.54.
Hedge funds and other institutional investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC bought a new stake in Corium International during the fourth quarter worth $123,000. DekaBank Deutsche Girozentrale bought a new position in shares of Corium International in the first quarter valued at about $167,000. California Public Employees Retirement System bought a new position in shares of Corium International in the fourth quarter valued at about $310,000. Two Sigma Advisers LP bought a new position in shares of Corium International in the fourth quarter valued at about $317,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Corium International by 126.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 18,416 shares during the period. 94.79% of the stock is currently owned by hedge funds and other institutional investors.
Corium International Company Profile
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.